HCPCS J3316 is officially defined as "Injection, triptorelin, extended-release, 3.75 mg." HCPCS J3316 is referenced in 8 tracked payer policy changes from Anthem BCBS, WellCare, and 2 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for HCPCS J3316 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Effective August 1, 2026, Anthem Virginia is implementing prior authorization, quantity limits, step therapy, and site of care requirements for 13 specialty pharmacy medications. Billing teams must update systems to require prior authorization for these drugs before dispensing and verify medical necessity documentation. Patients currently receiving these medications without prior auth will need authorization for continued coverage.
Effective August 1, 2026, Anthem Georgia is implementing new prior authorization, quantity limit, step therapy, and site of care requirements for 17 specialty pharmacy medications. Billing teams must update systems to require prior authorization for these drugs before the effective date, as patients currently receiving these medications without authorization will now require approval for continued use.
Beginning January 1, 2026, the procedure codes in this Centene bulletin require prior authorization through Evolent, which manages prior authorizations for Centene in medical oncology, radiation oncology, pediatric and dose optimization, and cardiology. The change applies to all Ambetter (Marketplace), Medicaid and Medicare products offered by Centene. The code table includes anti-emetics, bone metastasis drugs, cancer treatment drugs, and supportive medications such as iron products, ESAs, myeloid growth factors and immune globulins.
Effective August 1, 2026, Anthem Blue Cross specialty pharmacy policies are changing for New York commercial plans. Seven specialty drugs now require prior authorization, quantity limits, step therapy reviews, or site of care determinations. Billing teams must implement these requirements in their systems to avoid claim denials for patients currently receiving these medications without prior auth.
Effective August 1, 2026, Anthem is implementing new prior authorization, quantity limit, step therapy, and site of care requirements for 16 specialty pharmacy medications across multiple clinical criteria documents. Billing teams must update systems to require prior authorization for these drugs and verify step therapy status (non-preferred medications require step therapy) before claims submission. Patients currently receiving these medications without authorization may be affected, requiring proactive outreach.
Aetna considers gonadotropin-releasing hormone (GnRH) analogs and antagonists medically necessary for commercial plan members only for the specific indications listed for each drug, including leuprolide, goserelin, histrelin, triptorelin, degarelix, cetrorelix and ganirelix, and treats all other indications as experimental, investigational or unproven. Each drug has separate criteria for initial approval and for continuation of therapy, and continuation for prostate cancer requires clinical benefit such as serum testosterone less than 50 ng/dL and no unacceptable toxicity. Precertification is required for the prostate cancer indication, and gender dysphoria treatment for members under 18 must be prescribed by or in consultation with a provider specialized in the care of transgender youth who has collaborated care with a mental health provider.
Aetna covers gonadotropin-releasing hormone (GnRH) analogs and antagonists under its commercial medical plans for the indications the policy lists, including prostate cancer, breast cancer, ovarian cancer, central precocious puberty, endometriosis, uterine leiomyomata (fibroids), and ovulation induction or assisted reproductive technology. The policy also sets criteria for gender dysphoria treatment, including pubertal suppression in adolescents and gender transition, and for continuation of therapy. Aetna considers all other indications experimental, investigational, or unproven.
This Premera medical policy and coding update lists changes from September 2021. Effective September 1, 2021, Keytruda was added for high-risk, early-stage triple negative breast cancer, and varicose vein procedures such as ligation and stripping and phlebectomy were removed from the varicose vein policy. Coding changes effective September 1, 2021 removed medical necessity and prior authorization review for varicose vein codes 37500 through 37785, and coding changes effective September 3, 2021 added medical necessity and prior authorization review for alpha1-proteinase inhibitor codes J0256 and J0257 and gonadotropin releasing hormone analog codes J1950 through J9226.
Watch J3316
Get one email when a payer policy names J3316, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.
See every payer rule for J3316
Prior authorization lists, coverage criteria, NCCI edits and Medicare coverage articles for J3316 in one place.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.